Early market entry is often necessary to generate revenue and support the commercialisation of innovation. Jasdeep Singh, CEO of SingleTimeMicroneedles, explains how his company bridged the financing gap through navigating alternatives to traditional regulatory and go-to-market strategies.

Grant funding can be a catalyst for scientific and commercial progress. Adriann Sax, CEO & Co-Founder of Vetigenics, shares how strategic use of SBIR and foundation grants enabled the company to build a canine antibody platform, attract support from investors, and secure partners such as Merck Animal Health.